New Needle for Two-Needle Hemodialysis
Status unconfirmed · Phase 2/Phase 3
Conditions studied: End Stage Renal Disease
In brief
Our preliminary studies have demonstrated that an innovative new design of the hemodialysis venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the patient) with three jets is superior to the standard venous needle because it decreases the velocity and turbulence of the blood when compared with the standard venous needle, it is more efficient in the removal of toxins from the blood, and it is safe and effective. More importantly, our preliminary studies suggested that the new needle causes less damage to the dialysis vascular access and to circulating blood cells and less inflammation and oxidative stress. These will decrease medical complications, the high cost of care and death in dialysis patients. The current study will corroborate the finding of previous studies.
Key facts
- Study ID
- NCT01416896
- Run by
- Biomedical Enterprises Inc
- People needed
- 70
- Starts
- 2011-08-01
- Expected to finish
- 2012-09-01
- Last updated by the study team
- 2011-08-15
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- DaVita K Street Dialysis Center — Washington D.C., District of Columbia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.